AbbVie Aktie News

AbbVie's major drugs, Skyrizi and Rinvoq, are generating lots of sales. Realty Income's diversified portfolio provides plenty of protection and monthly income.

Dividend Kings underperformed SPY in 2025, up 4.47% vs. SPY's 17.7%, but select Kings outperformed the index. Twenty-two Dividend Kings are identified as both potentially undervalued and offering long-term expected annualized returns of at least 10%. Dividend growth for the Kings remains subdued at 5.81% for 2025, trailing the 2024 rate of 6.32%.

Consumer staples and healthcare can be durable industries to invest in. Costco is highly profitable and relies on its proven membership model.

AbbVie's guidance for the next few years implies robust revenue growth. Some of the company's products are performing even better than expected.

Amazon and Alphabet are key leaders in the AI race on top of their flagship businesses. Walmart benefits from consistent non-discretionary spending like groceries.

When inflation drops, as we saw in the November consumer price index report, the Federal Reserve typically continues to cut interest rates, making fixed-income alternatives less attractive.

AbbVie is a Dividend King that successfully navigated a challenging patent cliff. Coca-Cola is a household name that has survived and thrived for 139 years.

A single analyst's rating and price target, the consensus rating and price target, for that matter, have little value to investors without the proper context. The context is the sentiment strength and trend, which for stocks like PepsiCo NASDAQ: PEP, AbbVie NYSE: ABBV, and United Parcel Service NYSE: UPS, is strong and bullish.